Quote | MiNK Therapeutics Inc. (NASDAQ:INKT)
Last: | $0.9014 |
---|---|
Change Percent: | 0.0% |
Open: | $0.89 |
Close: | $0.9014 |
High: | $0.9227 |
Low: | $0.89 |
Volume: | 6,844 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | MiNK Therapeutics Inc. (NASDAQ:INKT)
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immun...
2024-05-14 11:52:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips MiNK Therapeutics (NASDAQ: INKT ) just reported results for the first quarter of 2024. MiNK Therapeutics reported earnings per share of -11 cents. This was above the analy...
Message Board Posts | MiNK Therapeutics Inc. (NASDAQ:INKT)
Subject | By | Source | When |
---|---|---|---|
Mink SITC 2022 posters are full of very | dia76ca | investorshub | 11/10/2022 4:12:55 PM |
$ARDS data will be important. BARDA support is | dia76ca | investorshub | 11/05/2022 6:48:54 PM |
Very interesting technology. Deserves a board. | dia76ca | investorshub | 11/03/2022 9:54:53 PM |
News, Short Squeeze, Breakout and More Instantly...
MiNK Therapeutics Inc. Company Name:
INKT Stock Symbol:
NASDAQ Market:
MiNK Therapeutics Inc. Website:
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immun...
Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American Thoracic Society (ATS) AACR presentation reported MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models...